临床试验/NCT04836429

NCT04836429终止1 期

Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease or Malignant Pleural Mesothelioma (MPM) - Phase I Study

Roswell Park Cancer Institute1 个研究点分布在 1 个国家目标入组 5 人开始时间: 2022年3月10日最近更新: 2026年2月4日

适应症

干预措施

试验速览

阶段: 1 期
状态: 终止
发起方: Roswell Park Cancer Institute
入组人数: 5
试验地点: 1
主要终点: Incidence of serious adverse events (SAE)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This phase I trial evaluates the side effects of intraoperative photodynamic therapy with porfimer sodium in enhancing the response to immunotherapy with an immune checkpoint inhibitor drug in patients with non-small cell lung cancer with pleural disease. Photodynamic therapy is a technique that that works by combining a photosensitizing agent (porfimer sodium in this trial) and an intense light source to kill tumor cells. Photodynamic therapy may decrease the patients' symptoms and improve their quality of life.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Histologically confirmed non-small cell lung cancer (NSCLC) with pleural disease and PDL1 expression < 50% or histologically confirmed diagnosis of malignant pleural mesothelioma not candidates for macroscopic complete resection
•Adequate blood tests 14 days prior to intraoperative PDT and with values within the ranges specified below.
•Hemoglobin ≥ 9.0 g/L
•Absolute neutrophil count ≥ 1.5 x 10^9/L
•Platelets ≥ 100 x 10^9/L
•Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (except participants with Gilbert's Syndrome, who are eligible with bilirubin ≤ 2.5 ULN)
•Alanine transaminase ≤ 2.5 xupper limit of normal (ULN), unless liver metastases or invasion are present, in which case it must be ≤ 5 x ULN
•Aspartate aminotransferase ≤ 2.5 x ULN, unless liver metastases or invasion are present, in which case it must be ≤ 5 x ULN
•The patient is on standard of care immunotherapy or combination of chemotherapy and immunotherapy with no evidence of progression or a candidate for chemoimmunotherapy as determined by the treating medical oncologist. Eligible patients that are currently on standard of care treatment will have the systemic therapy paused for 4-6 weeks prior to the surgery and intraoperative PDT and will resumed within 4-12 weeks after surgery following standard of care timeframe utilized for restarting systemic therapy after major surgical procedures to ensure adequate post-op recovery and tissue healing.
•Age >= 18 years old
•Life expectancy of at least 12 weeks.
•Subjects must have an Eastern Cooperative Oncology Group (ECOG) score of 0 - 1
•Subjects of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 6 months after surgery. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
•The subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent prior to receiving any study related procedure
•Platelet count < 100,000

排除标准

•Patients who received chemotherapy, chemoimmunotherapy or radiotherapy within <4 weeks (6 weeks for nitrosoureas or mitomycin C) or those who have not recovered from reversible adverse events prior to the scheduled surgery and intraoperative PDT.
•Patients with untreated or symptomatically unstable treated brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with treated and stable brain metastases (at least 28 days from last radiotherapy treatment) are eligible as long as steroids are not required for symptom management
•Patients with porphyria, or with known hypersensitivity to porphyrins or porphyrin-like compounds
•Absolute neutrophil count < 1500
•Left ventricular ejection fraction (LVEF) < lower level of normal (LLN)
•Total bilirubin > 2 mg/dL
•Creatinine clearance < 60 mL/min (Cockcroft Gault equation)
•Alkaline phosphatase (hepatic) > 3 times the upper normal limit (SGPT) > 3 times the upper normal limit
•NOTE: Roswell Park clinical lab blood chemistry is performed on plasma unless otherwise indicated
•Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
•Pregnant or nursing female subjects
•Unwilling or unable to follow protocol requirements
•Any condition which in the Investigator's opinion deems the subject an unsuitable candidate to receive porfimer sodium such as active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g. colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion:
•Patients with vitiligo or alopecia
•Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement
•Any chronic skin condition that does not require systemic therapy
•Patients without active disease in the last 5 years may be included
•Patients with celiac disease controlled by diet alone
•Patients with Hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Exceptions include past or resolved Hepatitis B (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) and patients positive for hepatitis C (HCV) antibody if polymerase chain reaction is negative for HCV RNA. HIV testing is not required in absence of clinical suspicion of HIV
•Received an investigational agent within 30 days prior to enrollment
•History of, or active autoimmune disorder, requiring systemic steroids or immunosuppressive agents. Exceptions allowed: patients with autoimmune dermatologic conditions not requiring systemic steroids or immunosuppressive agents (e.g. vitiligo, eczema, etc.), endocrine-related autoimmune conditions receiving appropriate hormonal supplementation. Use of immunosuppressant drugs such as steroids, azathioprine, tacrolimus, cyclosporine, etc. is not permitted within 4 weeks before recruitment (exception allowed is use of steroids as hormone replacement therapy or as supportive medication e.g. anti-emesis, contrast allergy, pre-medication, etc. or other short-course therapy less than 2 weeks continuously within 4 weeks of study treatment)

研究组 & 干预措施

Treatment (porfimer sodium, photodynamic therapy)

Experimental

Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy

干预措施: Porfimer Sodium (Drug)

Treatment (porfimer sodium, photodynamic therapy)

Experimental

Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy

干预措施: Video-Assisted Thoracic Surgery (Procedure)

Treatment (porfimer sodium, photodynamic therapy)

Experimental

Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy

干预措施: Photodynamic Therapy (Drug)

Treatment (porfimer sodium, photodynamic therapy)

Experimental

Patients receive porfimer sodium IV over 3-5 minutes 24-48 hours prior to standard of care VATS, followed by photodynamic therapy

干预措施: Intraoperative PDT (Device)

结局指标

主要结局

Incidence of serious adverse events (SAE)

时间窗: 28 days post study-related immunotherapy

Will be determined by recording the occurrence of SAE during the first 28 days post study-related immunotherapy. The SAE will be evaluated using the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

次要结局

Progression-free survival (PFS)(assessed up to 1 year)
Overall survival (OS)(assessed up to 1year)
Changes in the immune phenotype of peripheral blood CD8+ T cells(Baseline up to 1year)
Changes in platelet-to-lymphocyte ratio(Baseline up to 1 year)

研究者

发起方

Roswell Park Cancer Institute

申办方类型

Other

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

1 期

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by SurgeryRecurrent Non-Small Cell Lung CarcinomaStage IIA Non-Small Cell Lung CarcinomaStage IIB Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer

NCT01854684Roswell Park Cancer Institute8

终止

1 期

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck CancerRecurrent Head and Neck CarcinomaLocally Advanced Head and Neck Carcinoma

NCT03727061Roswell Park Cancer Institute5

撤回

不适用

Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavityStage I Squamous Cell Carcinoma of the Lip and Oral CavityStage I Squamous Cell Carcinoma of the OropharynxStage I Verrucous Carcinoma of the Oral CavityStage II Squamous Cell Carcinoma of the Lip and Oral CavityStage II Squamous Cell Carcinoma of the OropharynxStage II Verrucous Carcinoma of the Oral CavityTongue Cancer

NCT01718223Roswell Park Cancer Institute

已完成

1 期

NCT00470496Roswell Park Cancer Institute15

尚未招募

3 期

Effect of photodynamic therapy on chronic periodontitisChronic periodontitis.Chronic periodontitisK05.3

IRCT20231112060032N1Mashhad University of Medical Sciences35